Cytokinetics’ therapy beats beta blocker as monotherapy as it awaits combo approval

Three companies saw share price gains of over 20% on Monday, two of which were based on Phase III data presentations at the European Society of Cardiology Congress.

Cytokinetics Inc. (NASDAQ:CYTK) was the biggest mover of the three, with its 40% stock jump bringing its market cap to nearly $6 billion, after the company reported at the meeting that aficamten beat standard-of-care beta blocker metoprolol in the head-to-head Phase III MAPLE-HCM trial to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM). ...